ReviewStructural heart : the journal of the Heart Team2025
Choosing Between Tricuspid Repair or Replacement: Decision Algorithms.
Review in Structural heart : the journal of the Heart Team, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Novel Caval Valve Implantation in a Patient With Symptomatic Tricuspid Regurgitation and Right Heart Failure.JACC. Case reports · 2026Article
- Beyond the Valve: Heterotopic Tricuspid Intervention as a Therapy for the Failing Right Heart.JACC. Case reports · 2026Article
- Transcatheter Tricuspid Valve Replacement in a Patient With Small Right Atrium and Multiple Device Leads.JACC. Case reports · 2026Article
- Transcatheter Tricuspid Valve Replacement: Current Evidence, Device Landscape, and Future Directions.Cureus · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcatheter tricuspid valve (TV) interventions have transformed the treatment of TV disease. Among available therapies, transcatheter tricuspid edge-to-edge repair has shown favorable safety, symptom relief, quality-of-life improvement, and reduction of heart failure hospitalizations in selected patients with severe tricuspid regurgitation (TR). In complex cases, repair may not result in optimal TR reduction, whereas transcatheter TV replacement (TTVR) offers TR elimination, irrespective of the valve anatomy. However, TTVR is less widely available, requires long-term anticoagulation, and can lead to periprocedural adverse events. As device options expand, careful procedural selection has become increasingly important and must be guided by a comprehensive, multidisciplinary assessment. Key factors include TV anatomy, right ventricular function, pulmonary pressures and resistance, right ventricular-pulmonary artery coupling, endocardial device leads, bleeding risk, imaging quality, and anticoagulation tolerance. Multimodal imaging, including echocardiography and cardiac computed tomography, along with right heart catheterization is an essential step for procedural planning. In addition, preprocedural optimization with diuresis, rhythm control, and collaboration with heart failure and electrophysiology specialists are essential to ensure optimal procedural outcomes. Transcatheter tricuspid edge-to-edge repair and TTVR should be viewed as complementary therapies that each play a role in tailoring transcatheter TV intervention to individual anatomical and clinical patient characteristics. This review presents a framework based on evidence and experience for procedural selection, highlighting the importance of individualized evaluation and multidisciplinary care. A stepwise algorithm is proposed to support decision-making in patients with severe TR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.